Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
| Autor: | Michael Potter, Meral Beksac, Patrick Hayden, Uwe Platzbecker, Stephanie Nguyen-Quoc, Linda Koster, William Arcese, Alida Dominietto, Nicolaas Schaap, Monique C. Minnema, Edouard Forcade, Dirk Jan Eikema, Johanna Tischer, Virginie Gandemer, Ibrahim Yakoub-Agha, Hermann Einsele, Nicolaus Kröger, Angelo Michele Carella, Liesbeth C. de Wreede, Fabio Ciceri, Per Ljungman, Joan Hendrik Veelken, Jacob Passweg, Laure Vincent, Arancha Bermúdez, Adrian Bloor, Stefan Schönland, Attilio Olivieri |
|---|---|
| Přispěvatelé: | Hayden, P. J., Eikema, D. -J., de Wreede, L. C., Koster, L., Kroger, N., Einsele, H., Minnema, M., Dominietto, A., Potter, M., Passweg, J., Bermudez, A., Nguyen-quoc, S., Platzbecker, U., Tischer, J., Ciceri, F., Veelken, J. H., Ljungman, P., Schaap, N., Forcade, E., Carella, A. M., Gandemer, V., Arcese, W., Bloor, A., Olivieri, A., Vincent, L., Beksac, M., Schonland, S., Yakoub-Agha, I. |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Transplantation Conditioning Multivariate analysis Graft failure Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] Graft vs Host Disease Article 03 medical and health sciences 0302 clinical medicine Internal medicine Overall survival medicine Retrospective analysis Humans Sibling Multiple myeloma Retrospective Studies Transplantation business.industry Stem-cell therapies Incidence (epidemiology) Hematopoietic Stem Cell Transplantation Hematology Settore MED/15 Allografts medicine.disease surgical procedures operative 030220 oncology & carcinogenesis Immunotherapy Neoplasm Recurrence Local Multiple Myeloma business 030215 immunology |
| Zdroj: | Bone Marrow Transplantation, 56, 2367-2381 Bone Marrow Transplantation, 56, 10, pp. 2367-2381 Bone Marrow Transplantation, 56(10), 2367-2381. SPRINGERNATURE Bone Marrow Transplantation |
| ISSN: | 0268-3369 |
| Popis: | The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24–46%); Others 9% (0–17%), p p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21–40%) vs. 10% (1–20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24–0.67), p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink